

| Investigational Medicinal Product | | Mechanism | Disease Area of Research | Phase 1 | Phase 2 | Phase 3 | Countries Where Registered |
|---|--|-------------------|--|---------|---------|---------|---------------------------------|
| Zanubrutinib | | BTK inhibitor | CLL/SLL | | | | US, EU (CLL), and other regions |
| | | | WM | | | | US, EU, and other regions |
| | | | R/R FL | | | | US, EU, and other regions |
| | | | R/R MZL | | | | US, EU, and other regions |
| | | | TN MCL | | | | |
| | | | R/R MCL | | | | US and other regions |
| | | | R/R DLBCL with CD79B | | | | |
| | | | Previously treated B-cell malignancies | | | | |
| Zanubrutinib (Immunology & Inflammation) | | BTK inhibitor | Primary membranous nephropathy | | | | |
| | | | Lupus nephritis | | | | |
| Sonrotoclax | | BCL2 inhibitor | TN CLL ^a | | | | |
| | | | R/R WM | | | | |
| | | | R/R CLL | | | | |
| | | | R/R MCL | | | | |
| | | | R/R MM with t(11;14) | | | | |
| | | | AML/MDS | | | | |
| | | | B-cell malignancies | | | | |
| BGB-16673 | | BTK-targeted CDAC | B-cell malignancies | | | | |
| | | | R/R MCL and R/R CLL | | | | |
| BGB-21447 | | BCL2 inhibitor | B-cell malignancies | | | | |
| Tislelizumab | | anti-PD-1 | R/R cHL | | | | China |
| Ociperlimab | | anti-TIGIT | R/R DLBCL | | | | |

Safety and efficacy have not been established for investigational products and/or uses.

Abbreviations: AML, acute myeloid leukemia; BCL2, B-cell lymphoma 2; BTK, Bruton tyrosine kinase; CD79B, cluster of differentiation 79B; CDAC, chimeric degradation activating compound; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndromes; MM, multiple myeloma; MZL, marginal zone lymphoma; PD-1, programmed cell death protein 1; R/R, recurrent/refractory; SLL, small lymphocytic lymphoma; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TN, treatment naive; WM, Waldenström macroglobulinemia.

^aIn combination with zanubrutinib.

0424-MRC-036

May 2024

| Investigational Medicinal Product | Mechanism | Disease Area of Research | Phase 1 | Phase 2 | Phase 3 | Countries Where Registered |
|-----------------------------------|----------------|--|---------|---------|---------|----------------------------|
| Tislelizumab | anti-PD-1 | 1L NonSq NSCLC, 1L Sq. NSCLC, 2/3L NSCLC | | | | EU and other regions |
| | | 1L GC/GEJC | | | | China |
| | | 1L ESCC | | | | China |
| | | 2L ESCC | | | | US, EU, and other regions |
| | | 1L NPC | | | | China |
| | | 1L HCC, 2/3L HCC | | | | China |
| | | 1L UBC | | | | |
| | | LA ESCC | | | | |
| | | Neo/adj NSCLC | | | | |
| | | 1L ES-SCLC | | | | |
| | | NSCLC (subcutaneous formulation) | | | | |
| Ociperlimab | anti-TIGIT | 1L PD-L1 high NSCLC | | | | |
| | | Solid tumors | | | | |
| BG-68501 ¹ | CDK2 inhibitor | BC and solid tumors | | | | |
| BGB-43395 | CDK4 inhibitor | BC and solid tumors | | | | |
| BG-C9074 ² | B7H4-ADC | BC and solid tumors | | | | |

Safety and efficacy have not been established for investigational products and/or uses.

Abbreviations: ADC, antibody-drug conjugate; ADD: BC, breast cancer; CDK, cyclin-dependent kinase; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocellular carcinoma; 1L, first line; LA, locally advanced; NPC, nasopharyngeal carcinoma; NonSq, non-squamous; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; SCLC, small cell lung cancer; Sq, squamous; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; UBC, urothelial bladder cancer.

¹Ensem collaboration; BeiGene has global rights.

²DualityBio collaboration; BeiGene has global rights.

| Investigational Medicinal Product | Mechanism | Disease Area of Research | Phase 1 | Phase 2 | Phase 3 | Countries Where Registered |
|-----------------------------------|-----------------|----------------------------|---------|---------|---------|----------------------------|
| LBL-007 ¹ | anti-LAG3 | MSS-CRC | | | | |
| | | 1L ESCC | | | | |
| Surzebiclimab | anti-TIM3 | 1L HNSCC | | | | |
| Umbrella | IO combinations | 1L NSCLC ^a | | | | |
| | | Neo/adj NSCLC ^a | | | | |
| | | 2L+ NSCLC ^a | | | | |
| | | 1L HNSCC ^a | | | | |
| Zanidatamab ² | anti-HER2 BsAb | 2L HER2+ BTC | | | | |
| | | 1L HER2+ GEA | | | | |
| | | 1L HER2+ mBC/GC | | | | |
| BGB-A445 | anti-OX40 | Melanoma, RCC, UC | | | | |
| BGB-15025 | HPK1 inhibitor | Solid tumors | | | | |
| BGB-26808 | HPK1 inhibitor | Solid tumors | | | | |
| BGB-24714 | SMAC mimetic | Solid tumors | | | | |
| BGB-30813 | DGKζ inhibitor | Solid tumors | | | | |
| BGB-A3055 | anti-CCR8 | Solid tumors | | | | |



Safety and efficacy have not been established for investigational products and/or uses.

Abbreviations: 1L, first line; 2L, second line; BC, breast cancer; BsAb, bispecific antibody; BTC, biliary tract cancer; CCR8, the C-C motif chemokine receptor 8; CRC, colorectal cancer; DGKζ, diacylglycerol kinase ζ; GC, gastric cancer; GEA, gastroesophageal adenocarcinomas; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma HPK1, hematopoietic progenitor kinase 1; LAG3, lymphocyte activation gene 3; LS-SCLC, limited-stage small cell lung cancer; mBC, metastatic breast cancer; MSS, microsatellite stability; OX40, a member of the tumor necrosis factor (TNF) receptor family, also know as CD134; RCC, renal cell carcinoma; R/R, recurrent/refractory; SCLC, small cell lung cancer; SMAC, second mitochondria-derived activator of caspase; TIM3, T-cell immunoglobulin domain and mucin domain 3; UC, urothelial carcinoma.

^aMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

¹Leads Biolabs collaboration; BeiGene has ex-China commercial rights.

²Zymeworks/Jazz collaboration; BeiGene has APAC/ex Japan, AU, and NZ commercial rights.

PAGE 2 of 3

0424-MRC-036May 2024

| Investigational Medicinal Product | Mechanism | Disease Area of Research | Phase 1 | Phase 2 | Phase 3 | Countries Where Registered |
|-------------------------------------|----------------------|--|------------------|---------|---------|----------------------------|
| BGB-10188 | PI3Kδ inhibitor | Solid tumors | | | | |
| Pamiparib | PARP 1/2 inhibitor | 2L MTx gBRCAm PSOC | | | | |
| | | Advanced ovarian cancer | | | | China |
| Tarlatamab ¹ | DLL3 x CD3 | 2L SCLC | | | | US |
| | | 1L-ES-SCLC (initiation activities) | | | | |
| | | LS-SCLC (initiation activities) | | | | |
| | | 3L+ SCLC | | | | US |
| Xaluritamig ¹ | STEAP1 x CD3 | mCRPC | | | | |
| Blinatumomab ¹ | CD3 X CD19 | Pediatric R/R BP-ALL (initiation activities) | | | | |
| Goserelin microspheres ² | GnRH agonist | Breast and prostate cancer | | | | China |
| BGB-C354 | B7H3-ADC | Lung and GI cancers (preclinical) | Planned for 2024 | | | |
| BGB-B3227 | MUC1 x CD16A BsAb | Lung, GI and BC (preclinical) | Planned for 2024 | | | |
| BG-C477 | CEA-ADC | Lung and GI cancers (preclinical) | Planned for 2024 | | | |
| BGB-53038 | PanKRAS inhibitor 2G | Lung and GI cancers (preclinical) | Planned for 2024 | | | |
| BG-C137 | FGFR2b ADC | GI cancer (preclinical) | Planned for 2024 | | | |
| BGB-58067 | PRMT5 inhibitor | Lung and GI cancers (preclinical) | Planned for 2024 | | | |
| BG-60366 | EGFR-targeted CDAC | Lung cancer (preclinical) | Planned for 2024 | | | |

Safety and efficacy have not been established for investigational products and/or uses.

Abbreviations: 1L, first line; 3L, third line; ADC, antibody-drug conjugate; BC, breast cancer; BsAb, bispecific antibody; BTC, biliary tract cancer; BP-ALL, B-cell precursor acute lymphoblastic leukemia; CD3, cluster of differentiation 3; CD19, cluster of differentiation 19; DLL3, delta-like ligand 3; ES-SCLC, extensive-stage small cell lung cancer; gBRCAm, germlin BRCA mutation; GI, gastrointestinal; GnRH, gonadotropin-releasing hormone; HER2, human epidermal growth factor receptor 2; 2L, second line; LS-SCLC, limited-stage small cell lung cancer; mBC, metastatic breast cancer; mCRPC, metastatic castration-resistant prostate cancer; MTx, maintenance treatment; P13kδ, phosphoinositide 3-kinase-δ; PARP 1/2, poly (ADP-ribose) polymerase 1 and 2; PSOC, platinum-sensitive ovarian cancer; R/R, recurrent/refractory; SCLC, small cell lung cancer; STEAP1, six-transmembrane epithelial antigen of the prostate 1.

¹Amgen collaboration; BeiGene has China commercial rights.

²Luye collaboration; BeiGene has China rights.